YahooSeptember 15, 2026 at 10:16 AM NYLast Month
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
